Corbus Pharmaceuticals Holdings, Inc.
Support and Resistance Levels
Past performance
News About CRBP
All events for CRBP
All deals for CRBP
Financial Ratios
Financial Statements
CRBP vs Sector & Peers
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA. Website corbuspharma.com
Headquarters Norwood, MA, US